{"id":3288,"date":"2016-04-22T16:35:26","date_gmt":"2016-04-22T16:35:26","guid":{"rendered":"http:\/\/interactif.com\/enfold\/?p=3288"},"modified":"2022-05-03T18:26:19","modified_gmt":"2022-05-03T18:26:19","slug":"new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process","status":"publish","type":"post","link":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/","title":{"rendered":"New treatments for Duchenne muscular dystrophy: a stalled process"},"content":{"rendered":"<p>Initial <strong><em>Duchenne muscular dystrophy<\/em><\/strong> diagnoses usually come about around age 4 or 5 years, mostly in young boys. <em>Duchenne muscular dystrophy<\/em> often referred to as \u201cDMD\u201d, is the most severe form of muscular dystrophy.<\/p>\n<p>It is a degenerative disease that gradually weakens every muscle in the body, and that inevitably leads to premature death when afflicted kids reach their twenties. The corticosteroid-type treatments currently available \u2013 used for anti-inflammatory purposes \u2013 can prolong certain muscle functions; however, the side effects of these products are devastating in the long run!<\/p>\n<h3>A difficult approval process for effective treatments<\/h3>\n<p>For the first time in the history of Duchenne muscular dystrophy, innovative treatments that directly address the genetic causes of the disease are currently undergoing the FDA (<a href=\"http:\/\/www.fda.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">Food and Drug Administration<\/a>) approval process in the United States: <strong><em><a href=\"http:\/\/www.ptcbio.com\/en\/pipeline\/ataluren-translarna\/\" target=\"_blank\" rel=\"noopener noreferrer\">Ataluren<\/a> <\/em><a href=\"http:\/\/www.ptcbio.com\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">(PTC Therapeutic)<\/a><\/strong>,<strong> <a href=\"https:\/\/www.sarepta.com\/pipeline\/exon-skipping-duchenne\" target=\"_blank\" rel=\"noopener noreferrer\">Eteplirsen (Sarepta Therapeutics)<\/a><\/strong> and <strong><a href=\"http:\/\/www.biomarin.com\/products\/pipeline\/drisapersen-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noopener noreferrer\">Drisapersen (BioMarin)<\/a><\/strong>.<\/p>\n<p><strong><em>Ataluren<\/em><\/strong> is used in cases where on children happen to have a so-called \u201c<em><a href=\"https:\/\/fr.wikipedia.org\/wiki\/Mutation_non-sens\" target=\"_blank\" rel=\"noopener noreferrer\">nonsense<\/a><\/em>\u201d genetic mutation, while the action of the other two,<strong><em>\u00a0eteplirsen<\/em><\/strong> and <strong>d<em>risapersen<\/em><\/strong>, has to do with the \u201c<a href=\"https:\/\/en.wikipedia.org\/wiki\/Exon_skipping\" target=\"_blank\" rel=\"noopener noreferrer\">exon skipping<\/a>\u201d principle.<\/p>\n<p>Earlier this year, Sarepta Therapeutics, the pharmaceutical company developing <em>Eteplirsen<\/em>, was informed that there would be a delay in the process; the most recent news is that the matter is to be re-evaluated by a committee. Less than a month ago, it was <em>PTC Therapeutics<\/em>\u2019 turn to be told, much to their surprise, that certain elements of information were missing, despite the fact that its drug, Ataluren, had been approved in Europe (May 2014 \u2013 <a href=\"http:\/\/www.telegraph.co.uk\/news\/health\/news\/10851707\/Historic-first-ever-drug-for-Duchenne-muscular-dystrophy-approved.html\" target=\"_blank\" rel=\"noopener noreferrer\">read more<\/a>).<\/p>\n<h3>Undue delays for children who have no time to wait<\/h3>\n<p>The FDA\u2019s decisions influence those of all other jurisdictions. Failure to get approval for these pioneering treatments could have the effect of discouraging other pharmaceutical companies from developing alternative treatments for Duchenne muscular dystrophy. Worthy of mention is the fact that, although the data is currently deemed insufficient by the authorities, clinical trials have clearly demonstrated the positive effects of these treatments on children, with very few side effects.<\/p>\n<p>These delays sometimes cause pharmaceutical companies to lose significant value in the stock market, which is unfortunate. But even worse are the years of life the kids lose due to a blocked approval process that prevents them get the treatment they need.<\/p>\n<p><strong>In fact, the community has but one choice, and that is to take action\u2026 Otherwise, no treatment!<\/strong><\/p>\n<h3>Knowledge before action!<\/h3>\n<p>Of course, we do not at present have all the answers: <strong><em>Team La Force<\/em><\/strong>\u2019s mission is to develop expertise in the field and broadcast to the Canadian Duchenne Muscular Dystrophy community any relevant information pertaining to access to treatment.<\/p>\n<p>We\u2019ve given ourselves the mandate to inform the DMD community because we believe that disseminating knowledge is a great way to change things. With this in mind, we are announcing with great pleasure that <em>La Force<\/em> will be attending the <strong>FDA-AdComm conference<\/strong> to be held in Washington in late April. Our goal is to acquire as much knowledge as we can about the North American treatment approval processes and keep you informed.<\/p>\n<h3>What should you do as a parent of a child afflicted with Duchenne muscular dystrophy?<\/h3>\n<p>If your child is suffering from DMD, we suggest you do the following:<\/p>\n<ol>\n<li>In consultation with competent medical personnel, determine your child\u2019s specific genetic condition, find out the exact reason why he\/she is afflicted with DMD; it will guide you as to what treatments, existing or in development, are appropriate to his\/her situation;<\/li>\n<li>Learn about these treatments and work to get access to them: it\u2019s a good idea to consult with us, because, with time we\u2019ve learned a lot on the subject matter;<\/li>\n<li>Communicate with the people around you and share the information in order to raise awareness about the disease, about the availability of new treatments and about the long and laborious approval processes;<\/li>\n<li>Follow us on the web and on social networks in order to stay abreast of developments and benefit from the support of the DMD community.<\/li>\n<\/ol>\n<h2><strong><em>Link about\u00a0New treatments for Duchenne muscular dystrophy<\/em><\/strong><\/h2>\n<p><strong><a href=\"https:\/\/www.facebook.com\/cdmd.ucla\/videos\/10154102538983559\/\" target=\"_blank\" rel=\"noopener noreferrer\">Ad-Comm<\/a><\/strong><\/p>\n<p><a href=\"https:\/\/www.sarepta.com\/pipeline\/exon-skipping-duchenne\" target=\"_blank\" rel=\"noopener noreferrer\">Sarepta Therapeutics<\/a><\/p>\n<p><a href=\"https:\/\/www.sarepta.com\/pipeline\/exon-skipping-duchenne\" target=\"_blank\" rel=\"noopener noreferrer\">Eteplirsen<\/a>\u00a0\u2013\u00a0<a href=\"https:\/\/www.youtube.com\/watch?v=hQhQwQh4FLg&amp;feature=youtu.be\" target=\"_blank\" rel=\"noopener noreferrer\">The Facts About Eteplirsen<\/a>\u00a0\u2013\u00a0<a href=\"http:\/\/www.uptickanalyst.com\/sarepta-therapeutics-inc-nasdaqsrpt-analysts-take-on-earnings\/\" target=\"_blank\" rel=\"noopener noreferrer\">Uptick Analyst<\/a>\u00a0\u2013 <a href=\"http:\/\/www.drugs.com\/history\/eteplirsen.html\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Approval Status<\/a>\u00a0\u2013\u00a0<a href=\"https:\/\/www.change.org\/p\/fda-please-accept-sarepta-s-new-drug-application-nda-for-eteplirsen\" target=\"_blank\" rel=\"noopener noreferrer\">FDA: Please accept Sarepta\u2019s New Drug Application (NDA) for Eteplirsen<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong><a href=\"http:\/\/www.biomarin.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Biomarin<\/a><\/strong><\/p>\n<p><a href=\"http:\/\/www.biomarin.com\/products\/pipeline\/drisapersen-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noopener noreferrer\">Drisapersen<\/a>\u00a0\u2013\u00a0<a href=\"http:\/\/www.drugs.com\/history\/kyndrisa.html\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Approval Status (Drisapersen (Kyndrisa)<\/a>\u00a0\u2013\u00a0<a href=\"http:\/\/www.businesswire.com\/news\/home\/20160114005843\/en\/CureDuchenne-Responds-FDA-Decision-Drisapersen-Duchenne-Muscular\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Decision on Drisapersen for Duchenne Muscular Dystrophy<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong><a href=\"http:\/\/www.ptcbio.com\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">PTC Therapeutics<\/a><\/strong><\/p>\n<p><a href=\"http:\/\/www.fiercebiotech.com\/story\/ptc-no-evidence-duchenne-md-efficacy-fda-barred-regulators-doors-ataluren\/2016-02-29\" target=\"_blank\" rel=\"noopener noreferrer\">Fierce Biotech<\/a>\u00a0\u2013\u00a0<a href=\"http:\/\/www.fiercebiotech.com\/story\/ptc-no-evidence-duchenne-md-efficacy-fda-barred-regulators-doors-ataluren\/2016-02-29\" target=\"_blank\" rel=\"noopener noreferrer\">PTC: With no evidence of Duchenne MD efficacy, FDA barred regulators\u2019 doors to ataluren<\/a><\/p>\n<p><a href=\"http:\/\/ir.ptcbio.com\/releasedetail.cfm?releaseid=936905\" target=\"_blank\" rel=\"noopener noreferrer\">Results from Phase 3 ACT DMD Clinical Trial of Translarna\u2122 (ataluren)<\/a>\u00a0\u2013 <a href=\"http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/rds-sdr\/drug-med\/rds-sdr-ataluren-186992-eng.php\" target=\"_blank\" rel=\"noopener noreferrer\">Ataluren at Health Canada<\/a>\u00a0\u2013 <a href=\"https:\/\/www.nice.org.uk\/news\/press-and-media\/nice-recommends-ataluren-for-treating-duchenne-muscular-dystrophy-caused-by-a-nonsense-mutation\" target=\"_blank\" rel=\"noopener noreferrer\">Recommandation\u00a0pour le remboursement\u00a0NICE (UK)<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"http:\/\/www.parentprojectmd.org\/site\/PageServer?pagename=Advocate_fdaguidance\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Draft Guidance on Duchenne<\/a><\/p>\n<p><a href=\"http:\/\/www.wsj.com\/articles\/the-fda-vs-austin-leclaire-1461281386\" target=\"_blank\" rel=\"noopener noreferrer\">The Wall Street Journal<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Initial Duchenne muscular dystrophy diagnoses usually come about around age 4 or 5 years, mostly in young boys. Duchenne muscular dystrophy often referred to as \u201cDMD\u201d, is the most severe form of muscular dystrophy. It is a degenerative disease that gradually weakens every muscle in the body, and that inevitably leads to premature death when [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3289,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-3288","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-treatments"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New treatments for Duchenne muscular dystrophy: a stalled process - La Force dmd<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New treatments for Duchenne muscular dystrophy: a stalled process - La Force dmd\" \/>\n<meta property=\"og:description\" content=\"Initial Duchenne muscular dystrophy diagnoses usually come about around age 4 or 5 years, mostly in young boys. Duchenne muscular dystrophy often referred to as \u201cDMD\u201d, is the most severe form of muscular dystrophy. It is a degenerative disease that gradually weakens every muscle in the body, and that inevitably leads to premature death when [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/\" \/>\n<meta property=\"og:site_name\" content=\"La Force dmd\" \/>\n<meta property=\"article:published_time\" content=\"2016-04-22T16:35:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-03T18:26:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/laforcedmd.com\/wp-content\/uploads\/2016\/07\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"815\" \/>\n\t<meta property=\"og:image:height\" content=\"355\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"La Force DMD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"La Force DMD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/\"},\"author\":{\"name\":\"La Force DMD\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/person\\\/c7bd653b3f3d7fa23ef1721673d744cb\"},\"headline\":\"New treatments for Duchenne muscular dystrophy: a stalled process\",\"datePublished\":\"2016-04-22T16:35:26+00:00\",\"dateModified\":\"2022-05-03T18:26:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/\"},\"wordCount\":768,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg\",\"articleSection\":[\"Treatments\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/\",\"name\":\"New treatments for Duchenne muscular dystrophy: a stalled process - La Force dmd\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg\",\"datePublished\":\"2016-04-22T16:35:26+00:00\",\"dateModified\":\"2022-05-03T18:26:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#primaryimage\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg\",\"contentUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg\",\"width\":815,\"height\":355},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New treatments for Duchenne muscular dystrophy: a stalled process\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#website\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/\",\"name\":\"La Force dmd\",\"description\":\"Dystrophie musculaire de Duchenne\",\"publisher\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/laforcedmd.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\",\"name\":\"La Force dmd\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/logo-la-force-dmd.jpg\",\"contentUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/logo-la-force-dmd.jpg\",\"width\":500,\"height\":125,\"caption\":\"La Force dmd\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/person\\\/c7bd653b3f3d7fa23ef1721673d744cb\",\"name\":\"La Force DMD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g\",\"caption\":\"La Force DMD\"},\"url\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/author\\\/la-force-dmd\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New treatments for Duchenne muscular dystrophy: a stalled process - La Force dmd","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/","og_locale":"en_US","og_type":"article","og_title":"New treatments for Duchenne muscular dystrophy: a stalled process - La Force dmd","og_description":"Initial Duchenne muscular dystrophy diagnoses usually come about around age 4 or 5 years, mostly in young boys. Duchenne muscular dystrophy often referred to as \u201cDMD\u201d, is the most severe form of muscular dystrophy. It is a degenerative disease that gradually weakens every muscle in the body, and that inevitably leads to premature death when [&hellip;]","og_url":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/","og_site_name":"La Force dmd","article_published_time":"2016-04-22T16:35:26+00:00","article_modified_time":"2022-05-03T18:26:19+00:00","og_image":[{"width":815,"height":355,"url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2016\/07\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg","type":"image\/jpeg"}],"author":"La Force DMD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"La Force DMD","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#article","isPartOf":{"@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/"},"author":{"name":"La Force DMD","@id":"https:\/\/laforcedmd.com\/#\/schema\/person\/c7bd653b3f3d7fa23ef1721673d744cb"},"headline":"New treatments for Duchenne muscular dystrophy: a stalled process","datePublished":"2016-04-22T16:35:26+00:00","dateModified":"2022-05-03T18:26:19+00:00","mainEntityOfPage":{"@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/"},"wordCount":768,"commentCount":0,"publisher":{"@id":"https:\/\/laforcedmd.com\/#organization"},"image":{"@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#primaryimage"},"thumbnailUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2016\/07\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg","articleSection":["Treatments"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/","url":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/","name":"New treatments for Duchenne muscular dystrophy: a stalled process - La Force dmd","isPartOf":{"@id":"https:\/\/laforcedmd.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#primaryimage"},"image":{"@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#primaryimage"},"thumbnailUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2016\/07\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg","datePublished":"2016-04-22T16:35:26+00:00","dateModified":"2022-05-03T18:26:19+00:00","breadcrumb":{"@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#primaryimage","url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2016\/07\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg","contentUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2016\/07\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process.jpg","width":815,"height":355},{"@type":"BreadcrumbList","@id":"https:\/\/laforcedmd.com\/en\/new-treatments-for-duchenne-muscular-dystrophy-a-stalled-process\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/laforcedmd.com\/en\/"},{"@type":"ListItem","position":2,"name":"New treatments for Duchenne muscular dystrophy: a stalled process"}]},{"@type":"WebSite","@id":"https:\/\/laforcedmd.com\/#website","url":"https:\/\/laforcedmd.com\/","name":"La Force dmd","description":"Dystrophie musculaire de Duchenne","publisher":{"@id":"https:\/\/laforcedmd.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/laforcedmd.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/laforcedmd.com\/#organization","name":"La Force dmd","url":"https:\/\/laforcedmd.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/laforcedmd.com\/#\/schema\/logo\/image\/","url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/logo-la-force-dmd.jpg","contentUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/logo-la-force-dmd.jpg","width":500,"height":125,"caption":"La Force dmd"},"image":{"@id":"https:\/\/laforcedmd.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/laforcedmd.com\/#\/schema\/person\/c7bd653b3f3d7fa23ef1721673d744cb","name":"La Force DMD","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1362e69258784090c887e017c49a0bab8291c910310241733859975cc5ae0c07?s=96&d=mm&r=g","caption":"La Force DMD"},"url":"https:\/\/laforcedmd.com\/en\/author\/la-force-dmd\/"}]}},"_links":{"self":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/3288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/comments?post=3288"}],"version-history":[{"count":1,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/3288\/revisions"}],"predecessor-version":[{"id":11229,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/3288\/revisions\/11229"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/media\/3289"}],"wp:attachment":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/media?parent=3288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/categories?post=3288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/tags?post=3288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}